Table 3 The distribution of medical costs by year.

From: Current treatments for endometriosis in South Korea: an analysis of nationwide data from 2010 to 2019

 

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

Cost ratio (crude)

Cost ratio (adjusted)

Total cost

510.4 (801.1)

511.8 (757.2)

511.3 (793.8)

503.5 (863.1)

604.3 (959.3)

558.1 (910.1)

602.4 (983.9)

532.9 (924)

604.4 (1064.6)

529.9 (989.7)

1.01 (1.00 to 1.02)

1.01 (1.00 to 1.03)

 Outpatient visits

270.4 (378.7)

260.5 (346.3)

212.1 (284.5)

221.6 (275)

250 (309.3)

232 (263)

231.9 (266.2)

230.4 (258.6)

263.3 (298.4)

221.3 (256)

0.99 (0.98 to 1.00)

0.99 (0.98 to 1.00)

 Admission

1583.4 (486.2)

1478.7 (474.3)

1701.5 (458.4)

2031.1 (637.1)

2264.9 (463.4)

2268.8 (594.5)

2210.6 (754.8)

2341.1 (805.9)

2547 (1197.9)

2482.1 (1032.4)

1.06 (1.05 to 1.07)***

1.06 (1.05 to 1.07)***

 Surgery

1506.8 (587.1)

1426.9 (552.1)

1554.8 (635.8)

1758.5 (826.6)

1999.8 (788.6)

2056.8 (849.3)

2089.6 (836.3)

2216.1 (942.8)

2439.9 (1170.5)

2358.1 (1182.2)

1.06 (1.05 to 1.07)***

1.06 (1.05 to 1.07)***

 Hormone therapy

456.3 (351)

449.3 (342.4)

390.9 (276.1)

359 (263.9)

374.4 (312.3)

329.1 (230.2)

316.7 (237.2)

317.4 (222.4)

339.6 (228.4)

249.5 (181)

0.95 (0.94 to 0.96)***

0.95 (0.94 to 0.96)***

  Estrogen or progesterone

21.8 (25.7)

30.9 (29)

23.3 (25.4)

144.5 (175.1)

281.8 (295.4)

253.8 (208.7)

253.9 (218.2)

268.3 (199.1)

278.1 (201)

183.4 (139.6)

1.15 (1.13 to 1.17)***

1.14 (1.12 to 1.16)***

   Dienogest

–

–

–

253.3 (179.4)

343.7 (296.5)

311.8 (194.2)

308.5 (205.9)

314.4 (182.6)

317 (186.8)

207.9 (132.6)

0.95 (0.93 to 0.96)***

0.95 (0.93 to 0.96)***

   Tibolone

22.3 (17.3)

32.0 (27.6)

25.5 (19.9)

31.6 (26.8)

22.4 (20.8)

25.4 (25.8)

23.1 (22.1)

24.0 (21.6)

23.7 (22.8)

18.6 (18.6)

0.97 (0.93 to 1.01)

0.96 (0.93 to 0.99)*

  GnRH analogues

548.9 (312.2)

525.7 (308.6)

433.6 (253.7)

412.7 (238.9)

367 (227.7)

335.1 (203.8)

320.7 (193.9)

299.5 (197.9)

320.8 (201.9)

295.7 (174.4)

0.93 (0.92 to 0.94)***

0.93 (0.92 to 0.94)***

   Leuprorelin

573 (309.4)

509.1 (304.5)

406 (220)

365.5 (181.5)

320.3 (191.1)

312.5 (182)

283.1 (150.3)

262.2 (137.3)

287.2 (145.2)

281.3 (156.8)

0.92 (0.91 to 0.93)***

0.92 (0.92 to 0.93)***

  1. The costs were provided with the mean (standard deviation) per one patient by year. Costs were calculated for patients who used corresponding medical services. Cost ratio was estimated with generalized linear regression with log-link gamma distribution. We presented crude and age-adjusted cost ratio per one year. Cost ratio for dienogest change was estimated with data after 2013. *P < 0.05; **P < 0.01; ***P < 0.001. GnRH gonadotrophin-releasing hormone, NSAIDs non-steroidal anti-inflammatory drugs.
Back to article page